{"": [126, 1189, 0], "INTRODUCTION": [1190, 6609, 0], "CV38\u2013142 neutralizes both SARS-CoV-2 and SARS-CoV pseudoviruses": [6619, 7928, 0], "CV38\u2013142 can be combined with either RBS or CR3022 cryptic site antibodies": [7929, 11564, 0], "CV38\u2013142 binds to a proteoglycan site on SARS-CoV-2 RBD": [11565, 15404, 0], "CV38\u2013142 uses a plethora of water-mediated interactions to aid in cross-reactivity with SARS-CoV-2 and SARS-CoV RBDs": [15405, 18938, 0], "CV38\u2013142 accommodates rather than competes with ACE2 binding to the RBD": [18939, 20713, 0], "CV38\u2013142 binds RBD in either \u201cup\u201d or \u201cdown\u201d state and could cross-link spikes": [20714, 23943, 0], "RESULTS": [6610, 23943, 1], "DISCUSSION": [23944, 27196, 0], "Expression and purification of SARS-CoV, SARS-CoV-2 and SARSr-CoV RBDs": [27220, 28644, 0], "Expression and purification of antibodies": [28645, 29617, 0], "Expression and purification of human ACE2, SARS-CoV-2 RBD and S-HexaPro for binding assay": [29618, 30622, 0], "Crystallization and X-ray structure determination": [30623, 32491, 0], "Expression and purification of recombinant spike protein for nsEM": [32492, 33818, 0], "nsEM sample preparation and data collection": [33819, 34868, 0], "Measurement of binding affinities and competition using biolayer interferometry": [34869, 36477, 0], "Measurement of competition using surface plasma resonance": [36478, 37556, 0], "Enzyme-linked immunosorbent assay (ELISA) measuring antibody binding to RBD": [37557, 38340, 0], "Pseudovirus neutralization assay and synergistic study": [38341, 41635, 0], "Shape complementarity analysis": [41636, 41788, 0], "MATERIALS AND METHODS": [27197, 41788, 1], "Supplementary Material": [41789, 41815, 0]}